A study on the withdrawal and reduced craving effect on the alcohol dependent patients with liver cirrhosis on calcium carbonates therapy..

Authors

  • Ohri Akanshi
  • Bansal Yogesh
  • Shahi Rakesh kumar

Keywords:

Alcohal dependent patients, Calcium carbonate, Sodium bicarbonate, CIWA-Ar, Acamprosate

Abstract

Calcium seems to be the active ingredient in acamprosate (Ca₂⁺ bis-acetyl-homotaurinate), an anti-craving drug, based on research done before it was tested on people. Higher levels of calcium in the blood caused by taking acamprosate have also been linked to better results in terms of longer periods of abstinence and less time to relapse in human clinical trials. Conversely, alcohol craving was associated with diminished calcium levels in individuals with alcohol dependence. The primary objective of the research was to examine the withdrawal and diminished craving effects in alcohol-dependent patients with liver cirrhosis undergoing calcium carbonate therapy.  A total of 78 alcohol-dependent participants received either calcium carbonate (400 mg + 10 μg vitamin D) or sodium bicarbonate (1,000 mg) daily for 28 days during inpatient alcohol withdrawal treatment. According to an intention-to-treat methodology, the calcium carbonate group had a faster decrease in withdrawal intensity (measured with CIWA-Ar) than the sodium bicarbonate subgroup. The calcium carbonate group had a much lower desire for alcohol (measured by OCDS) than the sodium bicarbonate group. Our research indicates that administering calcium carbonate to alcohol-dependent patients with liver cirrhosis during alcohol withdrawal mitigates both alcohol cravings and withdrawal symptoms. To facilitate the advancement of pharmacological therapies beyond Ca2+ bis-acetyl-homotaurinate, the mechanism of action must be elucidated

Downloads

Download data is not yet available.

References

Spanagel R, Vengeliene V. New pharmacological treatment strategies for relapse prevention. Curr Top Behav Neurosci. 2013;13: 583–609.

2. Kufahl PR, Watterson LR, Olive MF. The development of acamprosate as a treatment against alcohol relapse. Expert Opin Drug Discov. 2014 Nov;9(11):1355–69.

3. Pradhan G, Melugin PR, Wu F, Fang HM, Weber R, Kroener S. Calcium chloride mimics the effects of acamprosate on cognitive deficits in chronic alcohol-exposed mice. Psychopharmacology. 2018 Jul;235(7):2027–40.

4. Schuster R, Koopmann A, Grosshans M, Reinhard I, Spanagel R, Kiefer F. Association of plasma calcium concentrations with alco- hol craving: new data on potential pathways. Eur Neuropsychopharmacol. 2017 Jan;27(1): 42–7.

5. O’Brien CC. Intensive calcium therapy as an initial approach to the psychotherapeutic relationship in the rehabilitation of the compul- sive drinker. J Psychol. 1964 Jan;57:125–9.

6. Heilig M. Acamprosate: an alcoholism treatment that may not be what we thought. Neu-ropsychopharmacology. 2014 Mar; 39(4):781–2.

7. Mann K, Hoffmann S, Pawlak CR. Does acamprosate really produce its anti-relapse effects via calcium? no support from the PRE- DICT study in human alcoholics. Neuropsy-chopharmacology. 2016 Feb;41(3):659–60.

8. Spanagel R, Vengeliene V, Kiefer F. Reply to: does acamprosate really produce its anti-relapse effects via calcium? no support from the PREDICT study in human alcoholics. Neuro- psychopharmacology. 2016 Feb;41(3):661–2.

9. Blaine J, Chonchol M, Levi M. Renal control of calcium, phosphate, and magnesium homeostasis. Clin J Am Soc Nephrol. 2015 Jul 7; 10(7):1257–72.

10. Zhu K, Prince RL. Lifestyle and osteoporosis. Curr Osteoporos Rep. 2015 Feb;13(1):52–9.

11. Lopez-Larramona G, Lucendo AJ, Gonzalez- Delgado L. Alcoholic liver disease and changes in bone mineral density. Rev Esp Enferm Dig. 2013 Nov–Dec;105(10):609–21.

12. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun;4: 561–71.

13. Hautzinger M, Bailer M, Worall H, Keller F. Beck-depressions-inventar (BDI). Test- handbuch. 2. überarbeitete Auflage. Bern: Verlag Hans Huber; 1995.

14. Mann K, Hoffmann S, Pawlak CR. Does acamprosate really produce its anti-relapse effects via calcium? no support from the PRE- DICT study in human alcoholics. Neuropsy- chopharmacology. 2016 Feb;41(3):659–60.

15. Spanagel R, Vengeliene V, Kiefer F. Reply to: does acamprosate really produce its anti-relapse effects via calcium? no support from the PREDICT study in human alcoholics. Neuro- psychopharmacology. 2016 Feb;41(3):661–2.

16. Blaine J, Chonchol M, Levi M. Renal control of calcium, phosphate, and magnesium homeostasis. Clin J Am Soc Nephrol. 2015 Jul 7; 10(7):1257–72.

17. Luisier M, Vodoz JF, Donath A, Courvoisier B, Garcia B. [25-hydroxy vitamin D deficiency with reduction of intestinal calcium absorption and bone density in chronic alcoholism]. Schweiz Med Wochenschr. 1977 Oct 29; 107(43):1529–33.

18. Zhu K, Prince RL. Lifestyle and osteoporosis. Curr Osteoporos Rep. 2015 Feb;13(1):52–9.

19. Lopez-Larramona G, Lucendo AJ, Gonzalez- Delgado L. Alcoholic liver disease and changes in bone mineral density. Rev Esp Enferm Dig. 2013 Nov–Dec;105(10):609–21.

20. Bading H. Nuclear calcium signalling in the regulation of brain function. Nat Rev Neuro- sci. 2013 Sep;14(9):593–608.

21. Sharma A, Schray A, Bartolovic M, Roesch- Ely D, Aschenbrenner S, Weisbrod M. Relationship between serum calcium and neuro- psychological performance might indicate etiological heterogeneity underlying cognitive deficits in schizophrenia and depression. Psychiatry Res. 2017 Jun;252:80–6.

22. Grützner TM, Listunova L, Fabian GA, Kramer BA, Flach D, Weisbrod M, et al. Serum calcium levels and neuropsychological performance in depression and matched healthy controls: reversal of correlation a marker of the aging cognitive clock? Psycho- neuroendocrinology. 2018 May;91:198–205.

23. Anty R, Canivet CM, Patouraux S, Ferrari- Panaia P, Saint-Paul MC, Huet PM, et al. Severe vitamin D deficiency may be an addition- al cofactor for the occurrence of alcoholic steatohepatitis. Alcohol Clin Exp Res. 2015 Jun; 39(6):1027–33.

24. Quintero-Platt G, González-Reimers E, Mar- tín-González MC, Jorge-Ripper C, Hernán- dez-Luis R, Abreu-González P, et al. Vitamin D, vascular calcification and mortality among alcoholics. Alcohol Alcohol. 2015 Jan;50(1): 18–23.

25. Schaefer TL, Davenport MH, Grainger LM, Robinson CK, Earnheart AT, Stegman MS, et al. Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxiety. J Neurodev Disord. 2017;9:6.

26. Marchi KC, Muniz JJ, Tirapelli CR. Hypertension and chronic ethanol consumption: What do we know after a century of study? World J Cardiol. 2014;6(5):283–94...

Downloads

Published

2025-06-13

How to Cite

1.
Akanshi O, Yogesh B, kumar SR. A study on the withdrawal and reduced craving effect on the alcohol dependent patients with liver cirrhosis on calcium carbonates therapy. J Neonatal Surg [Internet]. 2025 Jun. 13 [cited 2026 Apr. 14];14(32S):9968-73. Available from: https://jneonatalsurg.com/index.php/jns/article/view/9723

Issue

Vol. 14 No. 32S (2025): Journal of Neonatal Surgery

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.

Terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.